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uary 14, 2014.his study aimed to determine the usefulness of the combination of several electrocardiographic markers on risk
assessment of ventricular ﬁbrillation (VF) in patients with Brugada syndrome (BrS).Background Detection of high-/low-risk BrS patients using a noninvasive method is an important issue in the clinical setting.
Several electrocardiographic markers related to depolarization and repolarization abnormalities have been reported,
but the relationship and usefulness of these parameters in VF events are unclear.Methods Baseline characteristics of 246 consecutive patients (236 men; mean age, 47.6  13.6 years) with a Brugada-type
electrocardiogram, including 13 patients with a history of VF and 40 patients with a history of syncope episodes,
were retrospectively analyzed. During the mean follow-up period of 45.1 months, VF in 23 patients and sudden
cardiac death (SCD) in 1 patient were observed. Clinical/genetic and electrocardiographic parameters were
compared with VF/SCD events.Results On univariate analysis, a history of VF and syncope episodes, paroxysmal atrial ﬁbrillation, spontaneous type 1
pattern in the precordial leads, and electrocardiographic markers of depolarization abnormalities (QRS duration
120 ms, and fragmented QRS [f-QRS]) and those of repolarization abnormalities (inferolateral early
repolarization [ER] pattern and QT prolongation) were associated with later cardiac events. On multivariable
analysis, a history of VF and syncope episodes, inferolateral ER pattern, and f-QRS were independent predictors
of documented VF and SCD (odds ratios: 19.61, 28.57, 2.87, and 5.21, respectively; p < 0.05). Kaplan-Meier
curves showed that the presence/absence of inferolateral ER and f-QRS predicted a worse/better prognosis
(log-rank test, p < 0.01).Conclusions The combination of depolarization and repolarization abnormalities in BrS is associated with later VF events. The
combination of these abnormalities is useful for detecting high- and low-risk BrS patients. (J Am Coll Cardiol
2014;63:2131–8) ª 2014 by the American College of Cardiology FoundationSee page 2139Brugada syndrome (BrS) is a distinct form of idiopathic
ventricular ﬁbrillation (VF). BrS is characterized by a unique
electrocardiographic pattern consisting of a right bundle
branch blocklike morphology and ST-segment elevation
in precordial leads. Results of many studies (1–10) havecular Medicine, Okayama University Graduate
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dicine, National Cerebral and Cardiovascular
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3; revised manuscript received January 7, 2014,suggested that patients with syncope, particularly patients
with a spontaneous type 1 electrocardiographic pattern,
have a signiﬁcant risk of sudden cardiac death (SCD) or VF.In the remaining population of asymptomatic subjects, the
risk is lower, but not negligible (1,5). Therefore, assessment of
the risk of SCD and VF in patients with a Brugada-type elec-
trocardiogram (ECG) is clinically important, especially when
sporadic cases are detected during routine medical checkups.
Many markers for the development of VF in BrS have
been reported, including clinical markers of a family history
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2132of SCD (11), syncope with non-
prodromal episodes (12), episodes
of paroxysmal atrial ﬁbrillation
(PAF) (13), electrocardiographic
markers of a spontaneous type 1
electrocardiographic pattern, ex-
istence of late potential (14),
fragmented QRS (f-QRS) (15),
T-wave alternans after sodium
channel blocker injection (16), an
inferolateral early repolarization
(ER) pattern (17,18), a genetic
marker of SCN5A, a gene encod-
ing the cardiac sodium channel
(19), electrophysiological markers
of VF inducibility by programmed
electrical stimulation, abnormalrestitution properties, and ventricular effective refractory
period <200 ms (20). However, the relationship of these
markers and the usefulness of their combination have not
been sufﬁciently examined.
In this study, we examined risk markers, with a focus on
noninvasive surface electrocardiographic markers categorized
by depolarization and repolarization abnormalities, and
attempted to improve the accuracy of predicting and clas-
sifying high- and low-risk BrS patients.Figure 1 Representative Electrocardiograms of f-QRS and ER
(A) Fragmented QRS (f-QRS) was observed in lead V2. Note that there are 4 spikes
(arrows) in this lead. (B) Early repolarization (ER) pattern in the inferior leads. Note
that J-point elevation above the baseline (>1 mm) can be seen in leads III and aVF.Methods
Patient population and clinical data collection. We
retrospectively analyzed data from 246 consecutive patients
(236 men; mean age, 47.6  13.6 years) with a Brugada-
type ECG in Okayama University Hospital. All patients
showed a typical electrocardiographic Brugada pattern with
or without a sodium channel blocker (pilsicainide), which
was deﬁned previously (11). Informed consent was ob-
tained from all patients, and clinical data, including data on
age, sex, family history of SCD (younger than 45 years of
age), history of syncope episodes, history of VF episodes,
and VF induction during an electrophysiological (EP)
study were obtained from patient records. Follow-up data
deﬁned the start of follow-up as the ﬁrst visit and the
end of follow-up as death, arrhythmic events, or the last
visit.
Electrocardiographic measurements. Standard 12-lead
ECGs were recorded in the same way and were evaluated
for the R-R interval, PQ interval, QRS width, QT interval,
ST-segment level at the J point, and number of positive
spikes within the QRS complex in leads V1 through V3.
A spontaneous type 1 pattern was deﬁned as documenta-
tion by an ECG of a type 1 pattern in the absence of class I
antiarrhythmic drugs. The presence of a late potential was
evaluated by a signal-averaged ECG (ART 1200 EPX
[Arrhythmia　Research Technology, Inc., Fitchburg, Massa-
chusetts], noise level <0.3 mV, and high-pass ﬁltering of 40
Hz with a bidirectional 4-pole Butterworth). A late potentialwas considered positive when the following 2 criteria were
met: root mean square voltage of the terminal 40 ms in the
ﬁltered QRS complex of <20 mV and a duration of low-
amplitude signals <40 mV in the terminal ﬁltered QRS
complex of >38 ms (21).
The presence of f-QRS was deﬁned as an abnormal
fragmentation within the QRS complex as 4 spikes in
1 or 8 spikes in leads V1, V2, and V3, as described pre-
viously (15) (Fig. 1A).
An inferolateral ER pattern was deﬁned as an elevation of
the J-point in at least 2 consecutive leads. The amplitude
of the J-wave or J-point elevation had to be at least 1 mm
above the baseline level, either as QRS slurring or notching
in the inferior lead (II, III, and aVF), lateral lead (I, aVL,
and V4 to V6), or both, as described previously (17,18,22–25)
(Fig. 1B).
We divided the patients into the depolarization abnor-
mality (PQ interval >200 ms, QRS width 120 ms, positive
late potential, and f-QRS) group and the repolarization
abnormality (QT prolongation and inferolateral ER pattern)
group.
EP study. After obtaining written informed consent from
patients, an EP study was performed as described previously
(1,26) in all patients. The criterion for the induction of
ventricular arrhythmia was induction of sustained poly-
morphic ventricular tachycardia or VF by programmed
Table 1 Patient Characteristics
Male/female 236/10
Age, yrs, 47.6  13.6
Mean follow-up period, mo 45.1  44.3
History of syncope episodes 40 (16.3)
History of VF episodes 13 (5.3)
Family history of SCD 69 (28.0)
PAF 44 (17.9)
Spontaneous type 1 ECG 156 (63.4)
ER pattern 25 (10.2)
f-QRS 78 (31.7)
Positive LP 166/235 (70.6)
SCN5A gene mutation 17/123 (13.8)
VF induction during EP study 71/155 (45.8)
ICD implantation 63 (25.6)
VF or SCD event during follow-up 24 (9.8)
Values are n, mean  SD, n (%), or n/N (%).
ECG ¼ electrocardiogram; EP ¼ electrophysiological; ER ¼ early repolarization; f-QRS ¼ frag-
mented QRS; ICD ¼ implantable cardioverter-deﬁbrillator; LP ¼ late potential; PAF ¼ paroxysmal
atrial ﬁbrillation; SCD ¼ sudden cardiac death; VF ¼ ventricular ﬁbrillation.
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2133electrical stimulation from the right ventricular apex, right
ventricular outﬂow tract, or left ventricle with a maximum
of 3 extrastimuli at 2 cycle lengths.
Gene mutation analysis of SCN5A. This study was per-
formed in compliance with guidelines for human genome
studies of the Ethics Committee of Okayama University,
as described previously (13). In brief, all exons of SCN5A
were ampliﬁed by polymerase chain reaction from DNA
isolated from peripheral leukocytes of the patients. Genomic
DNA was extracted from peripheral blood leukocytes using
a DNA extraction kit (Gentra, Minneapolis, Minnesota)
and was stored at 30C until use. Twenty-seven exons of
the SCN5A gene were ampliﬁed with previously reported
intronic primers (13).
Statistical analysis. Statistical analysis was performed using
SPSS 17.0 for Windows (SPSS Inc., Chicago, Illinois).
Data are expressed as mean  SD or median (interquartile
range). A Student t test was performed to test for statistical
differences between 2 unpaired mean values, and categorical
data and percentage frequencies were analyzed by the
chi-square test. On univariate analysis, 9 predictors were
signiﬁcantly associated with arrhythmic events. Multivariate
analysis using Cox proportional hazards regression analysis
estimated those 9 predictors and was performed in search of
independent risk factors for arrhythmic events. This analysis
was based on a stepwise algorithm, with the p value set at
0.05 for entering and 0.1 for exclusion. The effects of ER
and f-QRS on arrhythmic events during the follow-up
period were evaluated using the log-rank test and were
described using a Kaplan-Meier curve. A p value < 0.05 was
considered statistically signiﬁcant.Results
Patient characteristics. Baseline patient characteristics are
summarized in Table 1. Sixty-nine patients (28.0%) had a
family history of SCD, 40 (16.3%) had history of syncope
episodes, and 13 (5.3%) had history of VF episodes. Gene
analysis showed that an SCN5A gene mutation was present
in 17 patients (13.8%). A spontaneous type 1 ECG pattern
was observed in 156 patients (63.4%). In the EP study,
VF was induced in 71 patients (45.8%), and 63 of them
(25.6%) had received an implantable cardioverter-deﬁbrillator
(ICD). During the follow-up period of 45.1  44.3 months,
fatal arrhythmic events occurred in 24 patients (23 appro-
priate ICD shocks caused by VF and 1 cardiac arrest during
sleep).
Clinical/genetic/electrocardiographic parameters and
cardiac events. Clinical and genetic parameters were
compared in BrS patients with and without cardiac events
during the follow-up period (Table 2). PAF episodes (9
of 24, 37.5% vs. 35 of 222, 15.8%, p ¼ 0.013), a history of
VF (9 of 24, 37.5% vs. 4 of 222, 1.8%; p < 0.001), a history
of syncope episodes (13 of 24, 54.2% vs. 27of 222, 12.2%;
p < 0.001), VF inducibility during the EP study (17 of 24,
70.8% vs. 54 of 131, 41.2%; p ¼ 0.007), and spontaneoustype 1 ECG pattern (22 of 24, 91.7% vs. 134 of 222, 60.4%;
p ¼ 0.002) were observed more often in VF/SCD patients
than in those without VF/SCD, but other parameters such
as age, sex, family history of SCD, and SCN5A gene mu-
tation were not different.
Among the electrocardiographic parameters of depolari-
zation abnormalities, QRS width 120 ms (8 of 24, 33.3%
vs. 29 of 222, 13.1%; p ¼ 0.015), and f-QRS (20 of 24,
83.3% vs. 58 of 222, 26.1%; p < 0.001) were observed
more often in patients with VF/SCD than in those without
VF/SCD. Among the ECG parameters of repolarization
abnormalities, a prolonged QTc interval >440 ms (7 of 24,
29.2% vs. 28 of 222, 12.6%; p ¼ 0.036), and inferolateral
ER pattern (8 of 24, 33.3% vs. 17 of 222, 7.7%; p < 0.001)
were observed more often in patients with VF/SCD than
in those without VF/SCD.
Multivariate analysis showed that the following 4 pa-
rameters were independent risk factors for arrhythmic
events: f-QRS (hazard ratio [HR]: 5.21; 95% conﬁdence
interval [CI]: 1.69 to 16.13; p ¼ 0.004), inferolateral ER
pattern (HR: 2.87; 95% CI: 1.16 to 7.14; p ¼ 0.023), a
history of VF episodes (HR: 19.61; 95% CI: 4.12 to 90.91;
p < 0.001), and a history of syncope episodes (HR: 28.57;
95% CI: 6.14 to 142.86; p < 0.001) (Table 2).
Patient characteristics with f-QRS. On multivariate
analysis, depolarization abnormalities of f-QRS were an
independent risk factor for arrhythmic events. Therefore,
clinical, genetic, and electrocardiographic data for patients
with and without f-QRS were analyzed again (Table 3).
There were no signiﬁcant differences in age, family history
of SCD, and incidence of the SCN5A gene mutation be-
tween patients with and without f-QRS. However, a history
of syncope episodes, a history of VF episodes, and VF
inducibility during EP study were more frequently observed
in patients with f-QRS than in those without f-QRS
(p ¼ 0.002, p ¼ 0.005, and p ¼ 0.002, respectively). PQ
Table 2 Characteristics of Patients With and Without VF/SCD During Follow-Up
VF/SCD þ VF/SCD 
Univariate Analysis Multivariate Analysis
OR 95% CI p Value HR 95% CI p Value
Clinical/genetic parameters
Male/female 23/1 213/9 1.029 0.125–8.490 0.649
Age (yrs), median (IQR) 47 (15) 48 (21) 0.835
History of syncope episodes 13 (54.2) 27 (12.2) 8.535 3.477–20.955 <0.001 28.571 6.135–142.857 <0.001
History of VF episodes 9 (37.5) 4 (1.8) 32.700 9.012–118.645 <0.001 19.608 4.115–90.909 <0.001
Paroxysmal AF 9 (37.5) 35 (15.8) 3.206 1.301–7.899 0.013 0.306
Family history of SCD 8 (33.3) 61 (27.5) 1.320 0.537–3.241 0.554
SCN5A gene mutation 4/23 (17.4) 13/100 (13.0) 1.409 0.414–4.799 0.396
VF induction during EP study 17/24 (70.8) 54/131 (41.2) 3.463 1.344–8.293 0.007 0.562
Spontaneous type 1 ECG pattern 22 (91.7) 134 (60.4) 7.224 1.657–31.491 0.002 0.114
Depolarization parameters
Positive f-QRS 20 (83.3) 58 (26.1) 14.138 4.638–43.093 <0.001 5.208 1.689–16.129 0.004
Positive LP 20/24 (83.3) 146/211 (69.2) 2.226 0.732–6.772 0.150
PQ interval >200 ms 8 (33.3) 40 (18.0) 2.275 0.911–5.681 0.069
QRS interval 120 ms 8 (33.3) 29 (13.1) 3.328 1.307–8.469 0.015 0.908
Repolarization parameters
ER pattern 8 (33.3) 17 (7.7) 6.029 2.258–16.103 <0.001 2.874 1.160–7.143 0.023
QTc >440 ms 7 (29.2) 28 (12.6) 2.853 1.087–7.490 0.036 0.608
Values are n, n (%), n/N (%), or median (IQR).
CI ¼ conﬁdence interval; HR ¼ hazard ratio; IQR ¼ interquartile range; OR ¼ odds ratio; other abbreviations as in Table 1.
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2134interval, QRS duration, and QTc interval were longer in
patients with f-QRS than in those without f-QRS (p ¼
0.037, p ¼ 0.001, and p ¼ 0.042, respectively), but the ER
pattern was not different between the groups. Spontaneous
type 1 ECG pattern and PAF episodes were more frequently
observed in patients with f-QRS than in those withoutTable 3 Characteristics of Patients With and With
f-Q
Clinical/genetic parameters
Male/female 7
Age, yrs 48.5
History of syncope episodes 2
History of VF episodes
PAF 2
Family history of SCD 2
SCN51 gene mutation 9/4
VF induction during EP study 34/5
ICD implantation 3
VF or SCD during follow-up 2
Electrocardiographic parameters
Duration of PQ interval, ms 184
Duration of QRS complex (ms), median (IQR) 10
Duration of QTc interval, ms 419
Amplitude at J-point V1 (mV), median (IQR) 0.1
Amplitude at J-point V2 (mV), median (IQR) 0.2
Amplitude at J-point V3 (mV), median (IQR) 0.1
Positive ER pattern
Spontaneous type 1 ECG 6
Positive LP 59/7
Values are n, mean  SD, median (IQR), n (%), or n/N (%).
Abbreviations as in Table 1.f-QRS (p < 0.001 and p ¼ 0.031, respectively). VF/SCD
episodes during follow-up were more frequently observed
in patients with f-QRS than in those without f-QRS
(p < 0.001).
Patient characteristics with an ER pattern. On multi-
variate analysis, repolarization abnormality of the ER patternout f-QRS
RSþ f-QRS p Value
6/2 160/8 0.511
 12.9 47.2  14.0 0.514
1 (26.9) 19 (11.3) 0.002
9 (11.5) 4 (2.4) 0.005
0 (25.6) 24 (14.3) 0.031
3 (29.5) 46 (27.4) 0.732
3 (20.9) 8/80 (10.0) 0.094
4 (63.0) 37/101 (35.9) 0.002
7 (47.4) 26 (15.5) <0.001
0 (25.6) 4 (2.4) <0.001
 29 176  26 0.037
8 (24) 100 (17) 0.001
 30 411  24 0.042
2 (0.15) 0.11 (0.10) 0.347
1 (0.21) 0.201 (0.17) 0.468
3 (0.12) 0.12 (0.12) 0.929
9 (11.5) 16 (9.5) 0.653
3 (80.8) 93 (55.4) <0.001
5 (78.7) 107/160 (66.9) 0.064
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2135was an independent risk factor for arrhythmic events.
Therefore, clinical, genetic, and electrocardiographic data
with and without an ER pattern were analyzed again
(Table 4). There were no signiﬁcant differences in age,
family history of SCD, incidence of SCN5A gene mutation,
positive late potential, a history of syncope episodes, f-QRS,
and VF inducibility during the EP study. However, VF/
SCD episodes during follow-up and a history of VF epi-
sodes were more frequently observed in patients with ER
than in those without ER (p ¼ 0.001 and p ¼ 0.005,
respectively).
Follow-up data. We next examined the follow-up data in
patients with f-QRS and ER. VF developed in 23 patients,
1 patient died suddenly during sleep, possibly because of
VF, and 1 patient died of a nonarrhythmic cause (pneu-
monia) during the follow-up period.
Figure 2 shows the results of Kaplan-Meier analyses of
fatal arrhythmic events in patients with and without f-QRS
(Fig. 2A) or an ER (Fig. 2B) pattern. Patients with f-QRS
or ER had a signiﬁcantly worse prognosis than did patients
without those parameters (p < 0.001 and p < 0.001,
respectively).
Figure 3 shows results of the combination analysis of
f-QRS and ER parameters. Patients with both f-QRS and
ER parameters had a signiﬁcantly higher frequency of
fatal arrhythmic events than did patients without both pa-
rameters (p<0.001). Moreover, patients with both f-QRS
and ER parameters had a signiﬁcantly higher frequency
of arrhythmic events than did patients with f-QRS alone
(p ¼ 0.045) (Fig. 3).Table 4 Characteristics of Patients With and With
E
Clinical/genetic parameters
Male/female 2
Age (yrs), median (IQR) 4
History of syncope episodes
History of VF episode
PAF
Family history of SCD
SCN5A gene mutation 2/1
VF induction during EP study 9/2
ICD implantation 1
VF or SCD during follow-up
ECG parameters
Duration of PQ interval, ms 190
Duration of QRS complex (ms), median (IQR) 9
Duration of QTc interval, ms 405
Amplitude at J-point V1 (mV), median (IQR) 0.1
Amplitude at J-point V2 (mV), median (IQR) 0.2
Amplitude at J-point V3 (mV), median (IQR) 0.1
Positive f-QRS
Spontaneous type 1 ECG 1
Positive LP 17/2
Values are n, mean  SD, median (IQR), n (%), or n/N (%).
Abbreviations as in Table 1.Discussion
The present study showed that the combination of f-QRS and
inferolateral ER pattern was associated with the development
ofVF inBrSpatients.Additionally, the combination of f-QRS
withER (depolarization and repolarization abnormalities) was
useful for identifying high- and low-risk BrS patients.
High-risk clinical parameters of VF development.
Previous studies have reported that syncope episodes
(especially in patients with prodrome), a history of VF, and
a family history of sudden death are associated with VF
events in BrS patients (3,4,12,20,27–29). In our study,
we also observed that syncope episodes and a history of
VF were independent predictors of later VF events. These
patients were symptomatic patients, and therefore, it is
reasonable to classify them as high-risk patients. However,
more patients have no symptoms with electrocardiographic
evidence of BrS (asymptomatic BrS patients). A recent study
suggested that these asymptomatic patients have a better
prognosis, but this is not negligible (1,5). Therefore, simple
risk assessment of these asymptomatic BrS patients is clin-
ically important, especially when sporadic cases are detected
during routine medical checkups.
Repolarization abnormalities in BrS. Many clinical data
support the importance of repolarization abnormalities for
VF development, such as T-wave alternans after sodium
channel blocker injection (16) and ST-segment elevation
after exercise (30) or full-stomach status (31).
An ER pattern is considered to be a benign electrocar-
diographic phenomenon affecting 2% to 5% of the generalout ER
Rþ ER p Value
3/2 213/8 0.269
3 (23) 49 (20) 0.820
5 (20.0) 35 (15.8) 0.383
5 (20.0) 8 (3.6) 0.005
3 (12.0) 41 (18.6) 0.584
7 (28.0) 62 (28.1) 0.995
5 (13.3) 15/108 (13.9) 1.000
1 (42.9) 62/134 (46.3) 0.770
3 (52.0) 50 (22.6) 0.001
8 (32.0) 16 (7.2) 0.001
 34 177  26 0.053
9 (17) 104 (20) 0.335
 27 414  26 0.097
4 (0.14) 0.11 (0.12) 0.306
1 (0.25) 0.20 (0.16) 0.505
7 (0.17) 0.12 (0.11) 0.069
9 (36.0) 69 (31.2) 0.653
4 (56.0) 142 (64.3) 0.417
3 (73.9) 149/212 (70.3) 0.717
Figure 2 Kaplan-Meier Analysis of VF/SCD Events
Ventricular ﬁbrillation (VF)/sudden cardiac death (SCD) were observed often in
the presence of fragmented QRS (f-QRS) (A), and early repolarization (ER) (B).
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2136population and is most commonly observed in young men
(32,33). Recently, an ER pattern has been shown to be an
additional risk marker for VF development, especially in
inferolateral leads, in patients with BrS (17,18). Our ﬁnding
that repolarization abnormalities were independently asso-
ciated with VF development is in agreement with these
previous ﬁndings.Figure 3 Kaplan-Meier Analysis of VF/SCD Events
Ventricular ﬁbrillation (VF)/sudden cardiac death (SCD) were often observed in
the combination of depolarization (fragmented QRS [f-QRS]) and repolarization
abnormalities (early repolarization [ER] pattern).Depolarization abnormalities in BrS. In addition to
repolarization abnormalities, recent observations have
suggested that VF development in BrS is associated with
conduction disturbances, such as prolongation of the PQ
interval (34), a wide QRS complex (35), a positive late
potential (36), and f-QRS (15,20). A recent study showed
that f-QRS is the strongest predictor of VF development
in BrS (20). The usefulness of f-QRS for identifying pa-
tients at high risk of various cardiac diseases, including
cardiac sarcoidosis, arrhythmogenic right ventricular car-
diomyopathy, and acute coronary syndrome (37), has been
reported. Our ﬁnding that f-QRS (depolarization abnor-
mality) was an independent predictor of VF development
is in agreement with those results. We also found that
f-QRS was associated with other depolarization abnor-
malities, such as a prolonged PQ and QRS interval,
indicating that depolarization abnormalities in the atrium
and ventricle are an important factors for the development
of VF in BrS.
A QRS interval in lead V2 120 ms was found to be a
possible predictor of life-threatening ventricular arrhythmia
and/or syncope. Prolonged QRS duration as measured on
a standard 12-lead ECG has been shown to be associated
with ventricular arrhythmia (35). Additionally, a prolonged
QRS duration in precordial leads is prominent in symp-
tomatic patients, suggesting that delayed conduction of the
ventricle (depolarization) is important (29,38). However, on
multivariate analysis in our study, there were no signiﬁcant
differences in wide QRS complex between patients with and
without VF/SCD.
Combination of depolarization and repolarization
abnormalities. In this study, Kaplan-Meier analyses
showed that the combination of f-QRS (depolarization ab-
normality) and ER (repolarization abnormality) is useful for
predicting VF events in patients with BrS. Recently, f-QRS
was reported to be an important marker for the development
of VF (Torsades de pointes) in patients with acquired long
QT syndrome (typical repolarization abnormality disease)
(39), indicating that the combination of depolarization and
repolarization is important for the development of lethal
arrhythmia. We also found that VF seldom developed in
patients without any abnormalities during the follow-up
period in this study, suggesting that low-risk BrS patients
could also be identiﬁed using these markers.
We also investigated the clinical/electrocardiographic
characteristics of depolarization and repolarization abnor-
malities. Interestingly, there were many differences between
the groups (Tables 3 and 4). Patients with f-QRS had more
depolarization abnormalities than those without f-QRS,
such as prolonged PQ and QRS intervals. In contrast, pa-
tients with an ER pattern had no differences in these
markers, suggesting that the genesis of each of these ab-
normalities is intrinsically different.
Clinical implications. BrS is a heterogeneous disease.
Therefore, the mechanism of VF development differs in
each patient. Our results suggest that the combination of
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2137depolarization and repolarization abnormalities (f-QRS and
ER pattern) enables identiﬁcation of high- and low-risk
patients with BrS. In the clinical setting, VF induction
during EP study is still considered when deciding to implant
an ICD. Thus, we think that we should recommend an
EP study in a patient with an f-QRS and ER pattern, if
asymptomatic, or we do not need an EP study in an
asymptomatic patient with neither an f-QRS nor ER pattern.
Study limitations. First, the electrocardiographic features
of ER and other electrocardiographic markers are dynamic,
and thus the true prevalence of this coexistence is difﬁcult
to evaluate. Second, we analyzed only the coding regions of
SCN5A for mutations in this study, and the possibility of
mutations occurring in regions of the gene other than coding
regions or other gene mutations cannot be excluded. Third,
Nishii et al. (19) reported that SCN5A gene mutations are
associated with early and frequent VF recurrence, but not
with initial VF episodes. In our study, we did not ﬁnd a sig-
niﬁcant difference. Therefore, further studies on this issue
are required. Fourth, this study was a retrospective study.
A prospective study to estimate risk factors of BrS is required.
Last, there was a small number of endpoints, making it
difﬁcult to identify unique predictors in a multivariate model
reliably.
Conclusions
Our study shows that ER and f-QRS are independent risk
factors for arrhythmic events in patients with BrS. Patients
with both ER and f-QRS have a signiﬁcantly higher fre-
quency of arrhythmic events than do patients who have
neither ER nor f-QRS. Furthermore, when there is neither
ER nor f-QRS, arrhythmic events are minor.
Clinically, this study shows that the combination of
f-QRS (a marker of depolarization abnormality) and ER
(a marker of repolarization abnormality) is useful for esti-
mating the incidence of VF in patients with BrS.
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